GlassScriptPhysician profile
Joseph P Vice
NPI 1538169016
$317.74
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $85.36.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $73.52 | 2019 | |
| Therapeuticsmd, INC. | $36.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.10 | 2020 | |
| Abbvie INC. | $30.29 | 2019-2020 | |
| Bard Access Systems, INC. | $27.56 | 2019 | |
| Baxter Healthcare | $22.82 | 2020 | |
| Daiichi Sankyo INC. | $19.97 | 2019 | |
| Amag Pharmaceuticals, INC. | $18.52 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.04 | 2019 | |
| Covidien LP | $15.91 | 2019 | |
| Hologic Sales and Service, LLC | $15.09 | 2020 | |
| Avion Pharmaceuticals | $10.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Vice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.